Psych Capital is floating on Aquis so that it can take advantage of the opportunities in the fast-growing psychedelic medicines sector. There is increasing interest in treatments using psychedelics and thereby investment in this area. More than $2bn has been invested in psychedelic companies and there are 47 quoted companies around the world in the sector.
However, Psych Capital is focused on early-stage companies that it can help to grow by providing marketing services and data.
The investors taking shares in the placing are also being given existing shares. The board is confident that they a...
